S&P ASX All Technology

US Dollar vs AUD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

SANA Sana Biotechnology Inc

1.69

0.04 (2.42%)

04 Jan 2025 - Closed

Delayed by 15 minutes

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

12/16/2024

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

12/26/2023

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Christian Hordo

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Sana Biotechnology (NASDAQ:SANA)
Historical Stock Chart
From Dec 2024 to Jan 2025

Click Here for more Sana Biotechnology Charts.

Sana Biotechnology (NASDAQ:SANA)
Historical Stock Chart
From Jan 2024 to Jan 2025

Click Here for more Sana Biotechnology Charts.

Sana Biotechnology Inc News

Form 144 - Report of proposed sale of securities
Tuesday 17 December 2024 (3 weeks ago) • Edgar (US Regulatory)

Sana Biotechnology Announces Fast Track Designation for SC291 in Relapsed/Refractory Systemic Lupus Erythematosus
Tuesday 3 December 2024 (1 month ago) • GlobeNewswire Inc.

Form 144 - Report of proposed sale of securities
Wednesday 27 November 2024 (1 month ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Tuesday 26 November 2024 (1 month ago) • Edgar (US Regulatory)

Sana Biotechnology to Present at December 2024 Investor Conferences
Tuesday 26 November 2024 (1 month ago) • GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Saturday 9 November 2024 (2 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Saturday 9 November 2024 (2 months ago) • Edgar (US Regulatory)

Sana Biotechnology Reports Third Quarter 2024 Financial Results and Business Updates
Saturday 9 November 2024 (2 months ago) • GlobeNewswire Inc.

Sana Biotechnology Announces Increased Focus on Type 1 Diabetes and B-cell Mediated Autoimmune Diseases with the Potential to Deliver Clinical Proof of Concept Data Across Multiple Studies in 2024 and 2025
Tuesday 5 November 2024 (2 months ago) • GlobeNewswire Inc.

Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering Intelligence
Wednesday 23 October 2024 (2 months ago) • PR Newswire (US)

Form 144 - Report of proposed sale of securities
Tuesday 22 October 2024 (2 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Wednesday 9 October 2024 (3 months ago) • Edgar (US Regulatory)

More Sana Biotechnology Inc News Articles

Commonwealth Bank Of Aus...

JP Morgan Chase

Woodside Petroleum

Verizon Communications

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions